1. Home
  2. PRLD vs MSW Comparison

PRLD vs MSW Comparison

Compare PRLD & MSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • MSW
  • Stock Information
  • Founded
  • PRLD 2016
  • MSW 2012
  • Country
  • PRLD United States
  • MSW Hong Kong
  • Employees
  • PRLD N/A
  • MSW N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • MSW
  • Sector
  • PRLD Health Care
  • MSW
  • Exchange
  • PRLD Nasdaq
  • MSW NYSE
  • Market Cap
  • PRLD 73.7M
  • MSW 78.0M
  • IPO Year
  • PRLD 2020
  • MSW 2024
  • Fundamental
  • Price
  • PRLD $1.05
  • MSW $8.21
  • Analyst Decision
  • PRLD Strong Buy
  • MSW
  • Analyst Count
  • PRLD 2
  • MSW 0
  • Target Price
  • PRLD $4.50
  • MSW N/A
  • AVG Volume (30 Days)
  • PRLD 611.2K
  • MSW 424.3K
  • Earning Date
  • PRLD 02-13-2025
  • MSW 02-25-2025
  • Dividend Yield
  • PRLD N/A
  • MSW N/A
  • EPS Growth
  • PRLD N/A
  • MSW N/A
  • EPS
  • PRLD N/A
  • MSW 0.21
  • Revenue
  • PRLD $3,000,000.00
  • MSW $27,572,692.00
  • Revenue This Year
  • PRLD N/A
  • MSW N/A
  • Revenue Next Year
  • PRLD N/A
  • MSW N/A
  • P/E Ratio
  • PRLD N/A
  • MSW $39.70
  • Revenue Growth
  • PRLD N/A
  • MSW 26.09
  • 52 Week Low
  • PRLD $0.80
  • MSW $3.70
  • 52 Week High
  • PRLD $6.80
  • MSW $10.58
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 45.27
  • MSW N/A
  • Support Level
  • PRLD $0.98
  • MSW N/A
  • Resistance Level
  • PRLD $1.43
  • MSW N/A
  • Average True Range (ATR)
  • PRLD 0.12
  • MSW 0.00
  • MACD
  • PRLD -0.02
  • MSW 0.00
  • Stochastic Oscillator
  • PRLD 14.14
  • MSW 0.00

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About MSW MING SHING GROUP HOLDINGS LIMITED

Ming Shing Group Holdings Ltd is a holding company, which is primarily operated through its indirectly wholly-owned Hong Kong Operating Subsidiaries, MS (HK) Engineering Limited and MS Engineering Co., Limited. It is engaged in wet trades works, such as plastering works, tile laying works, brick laying works, floor screeding works and marble works. the company is mainly engaged in private-sector projects in Hong Kong. Its private sector projects mainly involve private residential developments and commercial developments. The project owners of its private sector projects are generally property developers, and its customers are generally main contractors and wet trades work subcontractors engaged under such projects.

Share on Social Networks: